Chinese authorities have approved Novo Nordisk's Ozempic

In April, Novo Nordisk received marketing authorization in China for the drug Ozempic, which is the firm’s newest injection-based GLP-1 product.

Photo: Novo Nordisk / PR

More than three years after the injection-based treatment Ozempic was approved in the EU and the US, Chinese authorities have now approved the treatment, according to Novo Nordisk's interim report for the first quarter of 2021, which was published early Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs